PLAT-02 and PLAT-05 are clinical trials investigating feasibility and efficiency of CD-19 and CD-22 specific CAR-T cells in infants with relapsed/refractory KMT2A-r B-ALL following lymphodepleting chemotherapy. Here, CD19 is linked to acute lymphoblastic leukemia.